CLINICAL EXPERIENCE WITH 6‐MERCAPTOPURINE IN HUMAN NEOPLASIA
暂无分享,去创建一个
This report is concerned with the results obtained from the oral administration of 6-mercaptopurine (6-MP) in 24 adult patients and 1 child with acute leukemia, 5 patients with chronic granulocytic leukemia, 1 patient with chronic lymphocytic leukemia, 2 patients with myeloma, and 9 patients with various types of miscellaneous metastatic cancers. Of the 25 patients with acute leukemia, 10 were lymphocytic, 7 were monocytic, and 8 were granulocytic. Six of the granulocytic leukemias were acute from onset, and 2 represented the acute terminal phase of chronic granulocytic leukemia.
[1] P. M. Aggeler,et al. Evaluation of 6-mercaptopurine in the treatment of leukemia; a preliminary report. , 1953, Stanford medical bulletin.
[2] C. P. Rhoads,et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. , 1953, Blood.
[3] S. Sternberg,et al. 6-Mercaptopurine: effects in mouse sarcoma 180 and in normal animals. , 1953, Cancer research.